'Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial' Response
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Science Inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
dose after neostigmine a routine reversal may prevent residual neuoutcome parameter of incidence of rNMB with other clinical studies may show external validity issues. In the Letter to the Editor, the authors have a request to explain these comparisons with other clinical studies; (3) The Letter to the Editor suggested that although their primary endpoint was the incidence of a train-of-four (TOF) ratio less than 0.9 at tracheal extubation, Baysal and her colleagues did not use TOF monitoring for extubation of the patients in their clinical study. They used only clinically apparent diaphragmatic movements for extubation. The authors of the Letter to the Editor, Neira-Somoza the administration of a lower dose of sugammadex to displace the use of neostigmine with a lower dose and earlier administration of sugammadex which is another future investigation of neuromuscular reversal agents.
Açıklama
Anahtar Kelimeler
Residual Neuromuscular Blockade, Multicenter
Kaynak
Journal Of Perianesthesia Nursing
WoS Q Değeri
Q3
Scopus Q Değeri
Cilt
37
Sayı
5
